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ARTICLE
Clinical responses to adoptive T-cell transfer can
be modeled in an autologous immune-humanized
mouse model
Henrik Jespersen 1, Mattias F. Lindberg1, Marco Donia2, Elin M.V. Söderberg1, Rikke Andersen2,
Ulrich Keller3,4, Lars Ny1, Inge Marie Svane2, Lisa M. Nilsson1 & Jonas A. Nilsson1
Immune checkpoint inhibitors and adoptive cell transfer (ACT) of autologous tumor-
inﬁltrating T cells have shown durable responses in patients with melanoma. To study ACT
and immunotherapies in a humanized model, we have developed PDXv2.0 — a melanoma
PDX model where tumor cells and tumor-inﬁltrating T cells from the same patient are
transplanted sequentially in non-obese diabetic/severe combined immune-deﬁcient/
common gamma chain (NOG/NSG) knockout mouse. Key to T-cell survival/effect in this
model is the continuous presence of interleukin-2 (IL-2). Tumors that grow in PDXv2.0 are
eradicated if the autologous tumor cells and T cells come from a patient that exhibited an
objective response to ACT in the clinic. However, T cells from patients that are
non-responders to ACT cannot kill tumor cells in PDXv2.0. Taken together, PDXv2.0 pro-
vides the potential framework to further model genetically diverse human cancers for
assessing the efﬁcacy of immunotherapies as well as combination therapies.
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The prognosis of metastatic cutaneous malignant melanomahas been historically dismal1 but recent developments intargeted therapies and immune therapies have resulted in
prolonged overall survival. The disease most often develops from
sun-exposed areas of the skin and hence has a high mutational
load with a strong ultraviolet (UV) signature2, 3. Besides the
obvious risk of causing oncogenic mutations, UV radiation may
also result in a tumor promoting inﬂammation4. On the other
hand, a high mutation load also poses a risk for the incipient
tumor cell to elicit an immune response by giving rise to
expression of so-called neoantigens5, 6. Indeed, spontaneous
regressions of melanoma7 have been described and it is possible
that the 5–10% of patients with metastatic disease that were cured
from their disease prior to checkpoint inhibitors and targeted
therapies1 exhibited a better immune proﬁle. Owing to the well-
established immunogenicity, melanoma has therefore been an
attractive disease for studying immune evasion and immu-
notherapy. Several strategies to boost immunity against mela-
noma have been tested including vaccines8, 9, interleukin-2
(IL-2)10, interferons11 and histamine but with limited success12.
Instead, cell-based techniques such as adoptive T-cell transfer
(ACT)13 or immune checkpoint inhibitory antibodies have
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Fig. 1 Effective in vitro cytotoxicity does not result in effective anti-tumoral activity in NOG mice. a Schematic representation of the humanization process
(PDXv2.0). b Melanoma cells from patient #33 (MM33) were transduced with a luciferase lentivirus. Cells were plated in a 96-well plate and were mixed
with post-REP TILs from the original tumor. Luciferin was added to the media and the viability of the luciferase-expressing tumor cells was measured in a
luminometer. The experiment was done in triplicates and the error bar represents± SEM. cMM33 cells were transplanted into ten NOG mice. 1 week after
transplantation, mice were randomized into two groups, one of which received a tail vein injection with autologous TILs. 45,000 U IL-2 was given daily for
3 days following TIL injection and thereafter twice weekly during 3 weeks. Tumor growth was measured using calipers. P-values are from a multiple t-test
analysis. d, e When robust progression was noted in all mice, the mice with the slowest and fastest growing tumors in each group were sacriﬁced and the
tumors were analyzed by immunohistochemistry (d, bar= 50 µm) or ﬂow cytometry e for indicated markers. When PD1 expression was observed, anti-PD1
antibody pembroluzimab was given to the mice twice weekly. The experiments shown were performed once
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yielded the most promising results14–16. Both antibodies directed
against cytotoxic T-lymphocyte-associated protein 4 (CTLA4;
ipilimumab) or programmed cell death protein-1 (PD1; nivolu-
mab and pembrolizumab) are approved for use in melanoma
patients. Although the response rates are signiﬁcantly lower as
compared to BRAF- and MEK-targeted therapies17–20, the
responses are often more durable21. An optimal treatment should
therefore provide the response rates of targeted therapies and the
durability of immunotherapies. If a monotherapy cannot achieve
this, perhaps a combination therapy can. Indeed, combination
therapy between BRAF inhibitors and immune therapy (anti-
PD1) has been shown to be superior compared to monotherapies,
at least in genetically engineered mouse models (GEMMs)22, 23.
However, if concomitant combination is tolerable in the clinic, or
if not, in which schedule the combination should be used is not
completely understood. An additional outstanding question is
also whether combinations of different types of immune therapies
such as checkpoint inhibitors and ACT would beneﬁt patients.
The NOD-SCID-IL2-receptor common gamma chain knock-
out (NOG or NSG) mouse has revolutionized the ability to grow
tumor-grafts from patients24. The lack of all lymphocytes,
including NK cells, and a polymorphism in SIRPa, the CD47
receptor, makes the model particularly amendable for growing
human cells25. Melanoma grafts grow especially well as patient-
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Fig. 2 Transgenic expression of human IL-2 enables NOG mice to support viability of TILs. a Changes in IL-2 plasma levels in NOG mice injected with
45,000 U IL-2 over time and steady-state levels of IL-2 in hIL2-NOG mice. b In vivo bioluminescence images over time of two hIL2-NOG transgenic mice
with different serum levels of hIL-2 injected with MM33 TILs labeled with a luciferase lentivirus. c Quantiﬁcation of radiance of luciferase-expressing
MM33 TILs growing in mice (from b) with different serum levels of IL-2. d In vivo bioluminescence images from different angles of tumor-bearing or non-
tumor-bearing hIL2-NOG transgenic mice injected with luciferase-expressing MM33 TILs. The experiments shown here were performed once
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derived xenografts (PDXs) with near complete take rate24, 26. Yet,
current melanoma PDXs are not suitable for studies of immune
therapy studies. The aim of this study was to investigate if the
effect of ACT in patients could be modeled in humanized mice in
a predictive manner and if therapeutic effects would be enhanced
by anti-PD1 therapy. Here we generate a novel model, PDXv2.0,
by extended humanization of the NOG mouse with tumor-
inﬁltrating T lymphocytes and human IL2.
Results
T cells can accumulate in autologous tumors in NOG mice.
Most melanoma tumors grow while being in the presence of
tumor-inﬁltrating T-lymphocytes (TILs). Under normal condi-
tions, these TILs do not mediate tumor regression, e.g., because of
upregulation of PD-L1-mediated immune suppression (exhaus-
tion)27, 28. In vivo, anti-PD-1 antibodies reactivate TILs causing
tumor regression15, 16. Interestingly, TILs can also be re-activated
in vitro by culturing pieces of melanoma biopsies in media
containing the T-cell growth factor IL-229, 30. The re-activated
TILs can be expanded to large quantities, and can mediate
durable complete tumor regressions, when re-infused back into
the individual patients13. We hypothesized that in vitro expanded
TILs should be able to kill autologous tumors in NOG mice when
adoptively transferred. If so, we would also be able to create a
model, PDXv2.0 (Fig. 1a), which could be used to study immune
therapy and combination therapies.
We used a rapid expansion protocol (REP) to expand TILs
from patient #33. These TILs came from a metastatic melanoma
(MM33) and were characterized by their very high in vitro
cytolytic capacity as measured by a viability assay and release of
interferon gamma (IFNγ) in co-cultures of TILs and tumor cells
(Fig. 1b). Immune phenotyping suggested that the majority of the
REP-TILs were cytotoxic effector memory cells (Supplementary
Fig. 1). We injected MM33 tumor cells into 10 NOG mice and
monitored tumor growth by caliper measurement. When the cells
had formed palpable tumors, we injected 20×106 autologous
MM33 TILs per mouse into ﬁve mice via the tail vein and treated
the mice with recombinant human IL-2, akin to the protocol used
in patients undergoing adoptive T-cell therapy. However,
injection of TILs barely caused any effect on tumor growth
(Fig. 1c).
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To investigate if TILs injected into NOG mice track the tumor
cells we sacriﬁced two mice per group with the smallest and the
biggest tumors, and analyzed their tumors by immunohisto-
chemistry (IHC) and ﬂow cytometry. The TILs found in the
tumor were T cells as evident from the presence of CD3+ cells by
IHC (Fig. 1d). However, even though the original in vitro
expanded and subsequently transplanted TILs did not express the
negative immune checkpoint protein PD-1, in vivo growth
resulted in induction of surface PD-1 expression of the TILs
(Fig. 1e), suggesting that the tumor cells communicated with the
TILs. We therefore treated the remaining mice in the tumor
growth study with clinical grade anti-PD-1 antibody pembroli-
zumab but this did not result in the desired tumor regression
(Fig. 1c).
TILs do not cause tumor regression in NOG mice. Despite
MM33 TILs were able to kill MM33 tumor cells in vitro, that they
were trafﬁcking to the tumor site in mice, and that anti-PD-1
antibodies were administered, no regression of tumors was
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observed in this model. One possibility for ineffectiveness of the
described procedure was that we had used TILs that would have
been incapable of causing effects in adoptive T-cell therapy in
patients as well. To test that hypothesis, we developed tumor cells
and corresponding TILs from patients that had participated in a
clinical trial of adoptive T-cell therapy31, with different levels of
response to TIL therapy (Supplementary Fig. 2a). We ﬁrst
established xenografts from the tumor cells and noted that most
grew at a rate feasible for testing in vivo (Supplementary Fig. 2b).
We therefore repeated our procedure (Fig. 1a) with the exception
that we randomized 15 mice into three different groups; one
group transplanted with tumor cells and that received pem-
brolizumab and IL-2; a second group transplanted with tumor
cells and TILs and that received IL-2, and a third group trans-
planted with tumor cells and TILs and that received pem-
brolizumab and IL-2. TILs from the completely responding
patient (#11) and non-responding patient (#29) failed to affect
the growth of the autologous tumor cells in mice. A slightly
protracted disease progression—but limited impact on overall
survival—was observed in tumor-bearing mice transplanted with
MM24 TILs (Supplementary Fig. 3). In the clinic, patient #24
exhibited a partial response following infusion with TILs but
underwent additional surgery to remove the remainder of the
tumor. After this, the patient has remained tumor free for over 3
years (Supplementary Fig. 2a). Finally, there was a weak tumor
suppressive effect of MM46 TILs but only when mice were also
treated with pembrolizumab (Supplementary Fig. 3). Taken
together, TILs can delay tumor growth in some mice but cannot
achieve regressions in NOG mice—even if the TILs came from
patients that responded to adoptive cell transfer (ACT) in the
clinical trial.
IL-2 is essential for tumor eradication in NOG mice. The fact
that we were unable to achieve appreciable tumor regressions by
adoptive TIL transfer into NOG mice made us hypothesize that a
crucial factor was missing or non-functional in mice, or that the
tumor was utilizing more ways to evade immunity besides PD-L1
expression. IL-2 is essential for T-cell expansion and it is possible
that the clinical grade IL-2 used here had a too short half-life or
the dosing schedule or dose selected32 was too low. Indeed, as
published before33, we observed that subcutaneous injection of
human IL-2 resulted in peak levels around 2 hrs, which were
vanished by 8 h (Fig. 2a). To circumvent this we obtained hIL2-
NOG transgenic mice that overexpress IL-2 by virtue of a CMV-
driven human IL2 transgene34. Measuring plasma levels of IL-2
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by enzyme-linked immunosorbent assay (ELISA) in offspring of
these transgenic mice revealed a large spread from basically no
IL-2 production to levels above 5 ng/ml, comparable to the peak
levels achieved by human IL-2 injection (Fig. 2a). To investigate if
these mice could support human T cells we transduced MM33
TILs with a luciferase-GFP virus and injected them into NOG or
hIL2-NOG transgenic mice. Reassuringly, TILs survived longer in
hIL2-NOG than in NOG mice, even in low-expressing trans-
genics, causing disseminated growth (Fig. 2b, c). Transplant of
TILs into tumor-bearing mice made the TILs accumulate at the
site of the tumor, suggesting a homing mechanism or that the
tumor can prevent systemic spread of T lymphocytes (Fig. 2d).
The TILs could also be detected by ﬂow cytometry in tumor
homogenates and the majority of T cells were CD8+ effector
memory cells, whereas in peripheral blood the CD4+ cells pre-
dominated (Supplementary Fig. 4).
To investigate if IL-2 was a limiting factor for curative effects of
ACT, we labeled MM33 tumor cells with luciferase and
transplanted them into hIL2-NOG mice. In contrast to the effects
in NOG mice (Fig. 1c), MM33 TILs injected in hIL2-NOG mice
were able to cause regression of MM33 tumor cells in mice
treated with pembrolizumab (Fig. 3a). Treatment was continued
until no bioluminescence signal could be detected (Fig. 3b),
suggesting the mice had undergone a complete response (CR). In
a repeat experiment we observed one hIL2-NOG mice carrying
MM33 tumor mouse that did not achieve a CR by MM TILs. This
mouse turned out to have lower serum IL-2 levels (Supplemen-
tary Fig. 5a). We therefore repeated the experiment using mice
with >2 ng/ml IL-2 or <1.5 ng/ml IL-2. This experiment shows
that 2 ng/ml or above is optimal to achieve CR in MM33 ACT
experiments (Fig. 4a). As expected, we also noted that addition of
pembrolizumab did not alter the already robust response to ACT
in hIL2-NOG mice (Supplementary Figs. 4a and 5a). In a
dose–response experiment we determined the minimal amount of
TILs to be used in successful ACT was 106 cells (Fig. 4b).
Next, we repeated the experiment using tumors and TILs from
complete responding patient #24. Two out of three mice
transplanted with MM24 tumor cells were as responsive to
MM24 TILs as those transplanted with MM33 tumor cells and
TILs but in the third mouse, regressions was not observed
(Supplementary Fig. 5b). A follow-up repeat experiment,
conﬁrmed that also the MM24 model required a minimum
concentration of 1.5 ng/ml plasma IL-2 to achieve regressions
(Fig. 4c). The IL-2 dependence prompted us to re-address the
original experiment (Fig. 1c) in NOG mice that did not result in
tumor regression. Indeed, establishing a higher dose plasma level
(Supplementary Fig. 5c) and daily injections of recombinant
human IL-2 for 16 days resulted in tumor regressions
(Supplementary Fig. 5d). Contrary to the hIL2-NOG mouse
model though, the response was not durable when injections were
stopped and only one mouse out of three was cured.
Conﬁdent that we had modeled ACT in mice, we were
interested in assessing whether or not the PDXv2.0 model
correlated with responses in the clinic. To that end we used six
different patients TILs and tumors (Supplementary Fig. 2a, b),
three responders’ cells and three non-responders’ cells. Unlike
that seen in NOG mice, the hIL2-NOG mice transplanted with
MM24, MM11 and MM04 tumor cells all responded to therapy
with autologous TILs, whereas those transplanted with MM29,
MM46 and MM05 tumor cells did not (Fig. 4c, d).
Melanoma can metastasize to many distant sites in patients. To
investigate if ACT in mice could achieve regression of
spontaneous metastasis MM33 tumors were surgically resected
from in hIL2-NOG mice that did not receive MM33 TILs. As
expected, surgical removal of the tumors caused a drop in
bioluminescence but relapse emerged around the area of resection
as well as in distant sites (Fig. 5a, b). When MM33 TILs were
injected, it resulted in clearance of metastatic disease from most
sites in three out of four mice. Taken together, ACT in hIL2-NOG
mice models ACT in patients not only when the tumors grow
subcutaneously.
Discussion
Here we model ACT in mice and describe a new PDX model
termed PDXv2.0 that is useful to study immune therapy in
humanized mice. To our knowledge this model is the ﬁrst to show
CRs of human tumor cells by autologous immune cells in a
immune compromised mouse model—thus recapitulating the
robust effects observed in some patients with malignant mela-
noma treated with immune therapy such as ACT or anti-PD1
antibodies. Besides developing the model, we also unravel bio-
logical insights into T-cell immune therapy. First, ACT in mice
correlates with results of the same patients’ cells in the clinic.
Second, transplanting autologous T cells to tumor-bearing NOG
mice is not sufﬁcient to achieve tumor eradication unless IL-2 is
supplied continuously, which is facilitated by using the hIL2-
NOG mice. Third, anti-PD1 therapy does not alleviate the need of
IL-2 in NOG mice. Our study therefore offers a proof-of-concept
that a PDX model could be used to screen patients' tumors and
TILs to predict responses to ACT and perhaps other types of
immune therapy, although to ﬁrmly establish this a larger and
prospective study is needed. A similar concept has already gained
traction for predicting targeted therapy35–37 but since PDX
models have note been useful in immune therapy studies to date,
this has not been tested hitherto.
A major ﬁnding of this paper is the apparent dependency of
TILs on continuous supply of IL-2. This is notable considering
the TIL therapy trials in patients that are currently performed to
assess the appropriate dosing of IL-2. The side effects observed
with IL-2 in patients historically are not trivial, often requiring
hospitalization. At least two currently registered trials are testing
the hypothesis that high-dose bolus dose IL2 can be avoided. In
one trial (ClinicalTrials.gov Identiﬁer: NCT01995344), a lower
dose is tested whereas in another (ClinicalTrials.gov Identiﬁer:
NCT01468818), which was recently terminated due to low
accrual rates, was testing to omit IL-2 altogether. Moreover, a
small pilot study (NCT00937625) has shown that CRs in patients
can be obtained by TIL therapy using daily low-dose IL-2 injec-
tions38. In the recently published phase II trial (NCT00937625) of
patients receiving TIL therapy and a lower, but continuous dose
of IL-2, similar response rates as trials using high-dose IL-2, was
demonstrated31. Learning from the mouse model described here
it seems plausible that omitting IL-2 would be unadvisable.
Instead, means to limit IL-2 toxicity by lower but continuous
dosing, or by using alternative forms of hIL-2 such as the so-
called IL-2 superkine could make TIL therapy more accessible to
the general oncology clinic39. The method described here can be
used to study potential improvements and guide the technical and
clinical development of immune therapy against melanoma and
possibly other diagnoses.
The PDXv2.0 model may also be used to study resistance
mechanisms to immune therapy and therapeutic responses to
combination therapies consisting of cancer immune therapy and
targeted therapies or chemotherapy. A clear advantage of the
PDXv2.0 model over, e.g., GEMMs is that the tumor cells and
TILs used can come from a biobank of many different patients or
lesions from the same patient, thus recapitulating the hetero-
geneous nature of the disease. Furthermore, the tumor cells being
human also enable the direct test of clinical agents that may have
been developed against human proteins. The drawbacks are
however potentially equally many. For instance, at this time we
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are unaware to what extent the immune suppressive environment
in the tumor of the patient is represented in the model. The
stroma and myeloid cells in our model is murine and hence is
unlikely to exert immune suppressive power. Another drawback
is that we were never able to show a beneﬁt of anti-PD1 since the
model was either curative or the tumors did not respond to ACT
at all. It is therefore possible that altering the protocol and use
fewer T cells is needed if combination studies of ACT and
checkpoint inhibitors such as anti-PD1 are to be successful.
Humanizing mice with respect to both tumor and immune
cells has been tested before using various approaches. In these
models, either bone marrow aspirates, CD34+ hematopoietic
stem cell injection (Hu-CD34-NSG)40, or peripheral blood
mononuclear cells (PBMC) has been transplanted into immune-
deﬁcient mouse models together with either autologous cells or
traditional cell lines41, 42. Although these models are also feasible,
the concern is primarily dealing with T-cell education and lack of
CRs. Besides being less effective, erroneously trained T cells and
other cells from the hematopoietic system frequently cause graft-
vs-host disease (GVHD). Indeed, a very recent GVHD study
demonstrates that NOG mice transplanted with human CD4+
T cells (but not CD8+ cells) from PBMC develop serious skin
phenotypes, alopecia, weight loss and death43. They also
demonstrate that CD8+ expand vigorously in hIL2-NOG mice
and cause weight loss and death by 8 weeks after transplantation.
Many of the experiments reported in our study were conducted
for >10 weeks and besides observing weight loss or large spleens
in some mice (Supplementary Fig. 6) that had been cured from
melanoma we never observe the dramatic skin phenotypes of
GVHD. On the other hand, as shown in Fig. 2, TILs home to the
tumor so in the absence of a tumor or target, perhaps a lym-
phoproliferative disease can occur in hIL2-NOG mice. We
hypothesize that PDXv2.0 does not develop GVHD for at least
three reasons: (i) the tumor cells transplanted does not contain
immune cells; (ii) the TILs have been selected in the patients to
recognize the tumor cells and may therefore be speciﬁc; and (iii)
the TIL cultures do not contain B-cells, macrophages or other
immune cells that also constitute major culprits in GVHD44, 45.
Future head-to-head comparisons are warranted to investigate
under which circumstance one model should be chosen over the
other. For instance, in our case we most often do not observe any
major effect of anti-PD1 therapy since the effect of ACT is suf-
ﬁcient to cause tumor clearance in responders, and that anti-PD1
therapy is not able to convert a non-responder into a responder.
Therefore, to study anti-PD1 therapy other models where the
T cells are less efﬁcient at tumor eradication should likely be
used46. Notably, the current method developed demonstrates that
it is possible to achieve CRs to TIL therapy in immune com-
promised mice thereby setting a new standard to aim for in model
development.
Methods
Generation of TILs. After informed consent and IRB approval (he Ethical Com-
mittee of the Capital region of Denmark), patient samples were obtained by sur-
gical specimen collection from patients with metastatic melanoma as part of a
clinical trial31. A metastatic lesion was cut into fragments of 1–2 mm2 that were
placed in separate wells in a 24 well-plate (Nunc) with 2 ml of culture medium
(90% RPMI 1640 (Invitrogen), 10% heat inactivated Human AB serum (HS,
Sigma-Aldrich), 6000 IU/ml recombinant human IL-2 (Aldesleukin, Novartis),
penicillin, streptomycin and fungizone (Bristol-Myers Squibb). Young TIL (yTIL)
cultures were obtained by pooling TILs from each fragment as previously descri-
bed47–49, before being cryopreserved. For use in PDX-ACT experiments, yTILs
were expanded using a standard small-scale REP49. In short, irradiated (40 Gy)
allogeneic feeder cells (2×107), CD3 antibody (clone: OKT3) (30 ng/ml) (Miltenyi),
10 ml culture medium, 10 ml REP medium (AIM-V, Invitrogen) supplemented
with 10% HS and 6000 IU/ml IL-2) and yTILs (1×105) were mixed in a 25-cm2
tissue culture ﬂask. Flasks were incubated upright at 37 °C in 5% CO2. On day 5,
half of the medium was replaced. On day 7 and every day thereafter, cells were split
into further ﬂasks with additional REP-medium as needed to maintain cell
densities around 1–2×106 cells/ml. On day 10–14, cells were harvested and
resuspended at 2×108 cells/ml of PBS (Lonza) supplemented with 300 IU/ml of IL-
2, before being intravenously transplanted to mice (100 µl, 20×106 TILs per
mouse). To enable in vivo tracking of the TILs, yTILs were transduced with len-
tiviral ﬁreﬂy luciferase immediately before initiating the REP.
Cell lines. All cell lines were established at the Center for Cancer Immune Therapy,
Herlev, Denmark. Autologous melanoma cell lines were identiﬁed by their mor-
phological appearance and growth pattern and established from the same tumor as
the TILs by serial passage of adherent cells in RPMI 1640 supplemented with 10%
fetal bovine serum (FBS) and 500 ng/ml of Solu-cortef, as previously described49.
The cell lines were transduced with pHAGE-GFP-luciferase lentivirus and clones
were obtained by single-cell cloning in 96-well plates. All cell lines were maintained
in complete medium (RPMI-1640 supplemented with 10% FBS, glutamine and
gentamycin), were regularly screened for mycoplasma by PCR and cultured at
37 °C with 5% CO2.
In vitro antitumor reactivity and cytotoxicity. Luciferase cell lines (clones or pool
of transduced cells) were plated at 5,000 cells/well in a 96 white well plate (Sarstedt)
and TILs were immediately added onto them at different ratios. After 24 h of
incubation at 37 °C and 5% CO2, 20 µl of supernatant was collected for analysis of
IFN-γ release by ELISA (as per manufacturers protocol, Diaclone). Luminescence
was assessed with a Perkin Elmer Victor 3 plate reader, after adding 100 µl of
luciferin (300 µg/ml) onto the cells.
Mouse experiments. All animal experiments were performed in accordance with
EU directive 2010/63 (regional animal ethics committee of Gothenburg #2014-36).
The ﬁrst passage of the different PDXes (so called ‘P1’) was obtained by injecting
2×105 cells mixed with equal volume of Matrigel (Corning) subcutaneously at the
ﬂank of 6–15 week old immunocompromised, non-obese severe combined
immune-deﬁcient interleukin-2 chain receptor γ knockout mice (NOG mice;
Taconic). P1 tumors with volumes above 200 mm3 were then extracted,
mechanically dissociated with and ﬁltered through a cell strainer, washed with and
resuspended in RPMI-1640 and ﬁnally transplanted in P2 treatment mice, either
NOG or human IL-2 transgenic NOG (hIL2-NOG) mice (Taconic). When luci-
ferase tumor cells were used, 2–4×105 cells mixed with Matrigel were transplanted.
Before treatment blood samples were collected from the hind leg vein (vena
saphena), for analysis of plasma hIL-2 levels by ELISA as per manufacturers
recommendation (BD Biosciences). Between 5 and 25 days following
transplantation in P2 mice, mice were divided into treatment groups of equal
proportions of tumor sizes and 20×106 autologous TILs were administered to the
predeﬁned mice through tail vein injection. Subcutaneous administrations of 2.75
µg IL-2 (45,000 IU, from Novartis) were given to the NOG mice at the same time as
the TILs were injected, during the next two consecutive days, and then bi-weekly
for 3 weeks. Alternatively, 2.75 µg IL-2 (≥45,000 IU, from Peprotech) was given
once daily for 16 days. Pembrolizumab (MK-3475, Merck Sharp & Dohme) diluted
in PBS was given intraperitoneally bi-weekly (250 µg in 100 µl).
Tumor volumes were measured by caliper at regular time points by an operator
that was not blinded to the group allocation. For in vivo visualization of Luc-
tumors or Luc-TIL distribution, mice were injected intraperitoneally with 100 µl
luciferin (30 mg/ml, PerkinElmer) before being anesthetized with isoﬂurane.
Luminescence quantiﬁcations were acquired in the regions of interest (tumor area
or whole animal body in case of Luc-TILs) using the IVIS Lumina Series II
(PerkinElmer) and associated software.
Immunohistochemistry. Xenograft tissues were ﬁxed in 4% formalin, dehydrated
and embedded in parafﬁn. Sections of 4 µm were mounted onto positively charged
glass slides and dried overnight (ON) at 37 °C. The slides were rehydrated and
antigen retrieval performed by pressure cooking in a citrate buffer, followed by
quenching in 3% H2O2 in methanol for 10 min and blocking in 2,5% normal horse
serum for 30 min. Slides were stained with CD3 (clone: A0452, Dako, dilution
1:500) and PD-L1 (clone: E1L3N, Cell Signaling Technology, dilution 1:200)
antibodies ON at 4 °C, followed by 1 h incubation with secondary HRP-linked anti-
rabbit antibody (MP-7401, Vector Laboratories). ABC peroxidase detection system
(Vector Laboratories) was used following the manufacturer’s instructions and
Diaminobenzidine (DAB) chromogen developed. The slides were ﬁnally counter-
stained with hematoxylin, dehydrated and mounted with Pertex.
Flow cytometry. TILs were washed once, resuspended at 200,000 cells/50 μl in
MACS-buffer and stained with the following ﬂuorochrome-conjungated anti-
bodies: Alexa Fluor 488 anti-human CD3 (clone: UCHT1), APC anti-human
CD279 (PD1) (clone: EH12.2H7), PE/Cy7 anti-human Tim-3 (clone F38-2E2)
(BioLegend). Cells were then washed and analyzed on an Accuri C6 ﬂow cytometer
equipped with the BD Accuri C6 software.
For detailed immune phenotypning, cells were analyzed by ﬂow cytometry at
the department of Clinical Immunology and Transfusion Medicine, Sahlgrenska
University Hospital (accredited to EN ISO 15189). For ex vivo characterization of
TILs in ACT treated mice, TILs were injected in hIL2-NOG mice bearing
established autologous tumors. Tumors were harvested 40 days after injection of
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TILs, homogenized using a tissue chopper (McIlwain) and ﬁltered repeatedly
through 70 and 40 μm cell strainers before analysis. For PBMCs, blood was
harvested from anesthesized mice through cardiac puncture 48 days after injection
of TILs. PBMCs were then isolated using Ficoll-Paque before analysis.
Statistical analysis. Values are presented as mean± S.E.M. when data is com-
bined. For statistical analyses, we used Graphpad Prism software: multiple t-test
(with Sidak corrections) for tumor growth curves and the log-rank test for survival.
All mouse experiments contained 3–5 mice per group (exact number speciﬁed in
ﬁgure legends). The sample size of ﬁve was pre-determined to be able to detect a
>30% suppression of growth in the experiments with NOG mice (power 0.80,
common standard deviation of 20%) but since we were able to achieve curative
effects in the hIL2-NOG mice, sample size was decreased to three (power >0.9).
p< 0.05 was considered statistically signiﬁcant. Since all mouse strains were gen-
erated and maintained on the same original inbred background (NOG), the var-
iation within each data set obtained by experiments with mice was assumed to be
similar. However, experimental assessment of variance was performed and revealed
a difference in effects of ACT based on levels of IL-2 (Fig. 4a, b and Supplementary
Fig. 5a, b). No randomization was used in these studies. We were not blinded to
group allocations during animal experiments.
Data availability. The authors declare that data supporting the ﬁndings of this
study are available within the article and its Supplementary Information ﬁles and
from the corresponding author upon reasonable request.
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